Biocatalyzed synthesis of antidiabetic drugs: A review



Downloads per month over past year

Alcántara, Cristina M. and Alcántara León, Andrés Rafael (2018) Biocatalyzed synthesis of antidiabetic drugs: A review. Biocatalysis & Biotransformation, 36 (1). pp. 12-46. ISSN 1024-2422

[thumbnail of Corrected Proofs_IBAB_A_1323887.pdf]

Official URL:


The biocatalyzed production of building blocks for synthesizing drugs is a very attractive research field, because of the sustainability introduced in a synthetic schedule when chemical steps are substituted by biocatalyzed protocols. In this article, we will show how different antidiabetic drugs, for treating diabetes mellitus Type 1 and Type 2, can be more efficiently and effectively synthetized with the help of different types of biocatalysts. The huge overall drug market for these drugs, as well as the great number of people suffering from diabetes (the prevalence of all types of diabetes is growing), makes this topic attractive enough to focus on more efficient synthetic protocols for preparing antidiabetic drugs. Examples covering biocatalyzed synthesis of insulin analogues, sensitizers (PPAR agonists), secretagogues (GLP-1 analogues, GPR119 agonists) and enzyme inhibitors (α-glucosidase inhibitors, DPP4-inhibitors, SGLT-2 inhibitors and 11β-HSD1 inhibitors) will be presented.

Item Type:Article
Additional Information:

RESEARCHER ID E-5660-2010 (Andrés Rafael Alcántara León)
ORCID 0000-0003-4856-4000 (Andrés Rafael Alcántara León)

Uncontrolled Keywords:Hypoglycemic agents, Diabetes, Enzymes, Drug marketing, Glucosidase inhibitors, Biocatalysis, Drugs, Green chemistry, Insulin analogues
Subjects:Medical sciences > Medicine > Gastroenterology and Hepatology
Medical sciences > Pharmacy > Pharmacology
Medical sciences > Pharmacy > Organic chemistry
ID Code:47274
Deposited On:20 Apr 2018 08:12
Last Modified:18 Aug 2021 11:16

Origin of downloads

Repository Staff Only: item control page